This week's roundup of Houston innovators includes Daniel Powell of Spark Biomedical, Carrie Colbert of Curate Capital, and Carson Hager of SafeFun. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — venture capital, medical devices, and software — recently making headlines in Houston innovation.

Daniel Powell, CEO of Spark Biomedical

A new medical device created in Houston is revolutionizing opioid withdrawal treatment. Photo via sparkbiomedical.com

Houston-based Spark Biomedical has created an opioid withdrawal treatment device known as the Sparrow Therapy System. It's worn over the ear and sends mild electrical signals to trigger cranial nerves that release endorphins that the body has stopped producing on its own during opioid use. These endorphins help the user to make clearer, more logical decisions as they come off of the drug.

"If you ask 100 people who've gone through opioid withdrawal, I would bet 99 of them will tell you they thought they were going to die," Spark BioMed CEO Daniel Powell says. "Giving them the ability to manage that is huge. It's the first step towards addiction recovery. It's not solving the addiction, but it is an absolute barrier to move forward."

Carrie Colbert, general partner at Curate Capital

Carrie Colbert saw an opportunity is funding female-founded companies, and she's taking it. Photo courtesy of Curate Capital

Carrie Colbert has gone from energy executive to fashion and lifestyle content creation to her latest venture — venture investment. With her multifaceted career, she's grown her network across industries and platforms and now some of her followers have become Curate Capital's limited partners.

"Instagram turned out to be one of the best networking tools for me," Colbert says. "You can connect with people wherever they are and wherever you are." Read more.

Carson Hager, president at SafeFun

A Houston entrepreneur created a free smartphone app to easily track and share COVID-19 testing results. Photo courtesy of SafeFun

Last year, Carson Hager felt helpless as he saw Houston restaurants and bars being shut down amid the COVID-19 pandemic.

"I was thinking what's it going to take for people to be able to feel comfortable to go back out again and go out to bars and restaurants, gyms, salons, club, etcetera," he says.

In April 2020, he decided to act. And with the help of a few programmer friends pulling long hours for about 100 days straight, Hager created SafeFun, a Houston-based digital health passport that allows users to voluntarily and easily share COVID-19 test results and information. Read more.

A Houston entrepreneur created a free smartphone app to easily track and share COVID-19 testing results. Photo courtesy of SafeFun

Houston tech-turned-hospitality entrepreneur launches global health passport

there's an app for that

The pandemic brought Houston hospitality entrepreneur Carson Hager — a self-described "recovering programmer" — back to his roots in an attempt to help people gather together once more.

After 20 years in the tech world — he sold his consumer-grade commercial software company Cynergy Systems to KPMG in 2014 —Hager founded the Hospitable Viking, known for popular local bars like Rosemont in Montrose and Cherry downtown.

"It gives me some chaos," he says of his new industry. "It's something to do that's a very different challenge."

But the pandemic added a new challenge and even more chaos in his industry. As restrictions were put in place in the spring of 2020 and many (including Hager himself) didn't feel comfortable dining and drinking in public, he watched as many in his industry lost their jobs, businesses, and sense of community.

"I live in restaurants and bars and I wouldn't have gone anywhere at that point," Hager says. "I was thinking, what's it going to take for people to be able to feel comfortable to go back out again and go out to bars and restaurants, gyms, salons, club, etcetera."

In April 2020, he decided to act. And with the help of a few programmer friends pulling long hours for about 100 days straight, Hager created SafeFun, a Houston-based digital health passport that allows users to voluntarily and easily share COVID-19 test results and information.

The free app extracts and analyzes PDF test results from a variety of COVID-19 tests including molecular/diagnostic, antigen and antibody tests. SafeFun then validates the test against records from 100 partnering testing centers, including the likes of Walgreens, CVS, and Walmart, to ensure that the results are credible and summarizes the information for users to easily share through the app or in person.

After completing the build out in September 2020, Hager and his small team of four approached various city governments with the hopes of having them come on board as partners and support using the app for business purposes. However, what they found was that users were more interested in using SafeFun for personal reasons.

After a few more weeks of programming, Hager and team released the consumer-facing version in late 2020. Currently SafeFun has about 12,000 users around the world, according to Hager. Today it's mainly used ahead of a small gathering with friends, when visiting family, or to date.

SafeFun also has the capability to process and analyze proof of vaccine and other tests for infectious diseases. However, the current road block in the COVID realm is that in the U.S. most vaccine providers do not provide digital for PDF documentation.

Still, Hager envisions various potential uses for SafeFun in the future: for cruises, air travel, and even STD testing. Or, as Hager says, "God forbid, future pandemics."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.